Skip to main
OPK
OPK logo

OPKO Health (OPK) Stock Forecast & Price Target

OPKO Health (OPK) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OPKO Health has identified an additional $10 million in annualized cost reductions, which is expected to enhance its financial performance moving forward. The BioReference Health (BRH) unit is close to achieving operational profitability, being only $3 million away from breaking even, excluding non-recurring costs, with full implementation of cost-saving measures anticipated in the latter half of 2025. Furthermore, OPKO is projected to achieve adjusted EBITDA positivity, as indicated by the $5.7 million in depreciation and amortization expense recorded in the first quarter.

Bears say

OPKO Health Inc. reported a disappointing earnings per share (EPS) of -$0.10, falling short of expectations due to non-recurring costs, indicating ongoing financial challenges. Additionally, the performance of the NGENLA segment was particularly concerning, generating only half of anticipated revenue and experiencing a decline compared to the previous year, which raises concerns about market demand and operational effectiveness. Overall, the combination of weak EPS reports and underperformance in key segments creates a negative outlook for the company's financial health and future growth prospects.

OPKO Health (OPK) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OPKO Health (OPK) Forecast

Analysts have given OPKO Health (OPK) a Buy based on their latest research and market trends.

According to 2 analysts, OPKO Health (OPK) has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OPKO Health (OPK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.